{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:42:17Z","timestamp":1790754137925,"version":"4.1.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1995,6,1]],"date-time":"1995-06-01T00:00:00Z","timestamp":801964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1995,6]]},"DOI":"10.1007\/bf02246288","type":"journal-article","created":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T08:53:36Z","timestamp":1132044816000},"page":"247-260","source":"Crossref","is-referenced-by-count":302,"title":["Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or \u201cEcstasy\u201d)"],"prefix":"10.1007","volume":"119","author":[{"given":"A. R.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02246288_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0892-0362(93)90067-X","volume":"15","author":"SF Ali","year":"1993","unstructured":"Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR, Paule MG, Slikker W (1993) Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the non-human primate. Neurotoxicol Teratol 15:91\u201396","journal-title":"Neurotoxicol Teratol"},{"key":"BF02246288_CR2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/sleep\/16.6.560","volume":"16","author":"RP Allen","year":"1993","unstructured":"Allen RP, McCann UD, Ricaurte GA (1993) Persistant effects of (+)-3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d) on human sleep. Sleep 16:560\u2013564","journal-title":"Sleep"},{"key":"BF02246288_CR3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jama.1993.03500070049022","volume":"269","author":"D Ames","year":"1993","unstructured":"Ames D, Wirshing WC (1993) Ecstasy, the serotonin syndrome and neuroleptic malignant syndrome - a possible link? JAMA 269:869","journal-title":"JAMA"},{"key":"BF02246288_CR4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.2042-7158.1961.tb11896.x","volume":"13","author":"BM Askew","year":"1961","unstructured":"Askew BM (1961) Amphetamine toxicity in aggregated mice. J Pharm Pharmacol 13:701\u2013703","journal-title":"J Pharm Pharmacol"},{"key":"BF02246288_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1126\/science.2911718","volume":"243","author":"DM Barnes","year":"1989","unstructured":"Barnes DM (1989) Neurotoxicity creates regulatory dilemma. Science 243:29\u201330","journal-title":"Science"},{"key":"BF02246288_CR6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/bmj.305.6863.1225-b","volume":"305","author":"PJ Barrett","year":"1992","unstructured":"Barrett PJ (1992) Ecstasy and dantrolene. BMJ 305:1225","journal-title":"BMJ"},{"key":"BF02246288_CR7","first-page":"911","volume":"242","author":"G Battaglia","year":"1987","unstructured":"Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain:quantification of neurodegeneration by measurement of [3H]-paroxetine-labelled serotonin uptake sites. J Pharmacol Exp Ther 242:911\u2013916","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0091-3057(88)90155-4","volume":"29","author":"G Battaglia","year":"1988","unstructured":"Battaglia G, Yeh SY, De Souza EB (1988a) MDMA-induced neurotoxicity parameters of degeneration and recovery of brain serotonin systems. Pharmacol Biochem Behav 29:269\u2013274","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02246288_CR9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","volume":"149","author":"G Battaglia","year":"1988","unstructured":"Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988b) Pharmacologic profile of MDMA (3,4-methylenedioxy-methamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159\u2013163","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/adc.67.9.1114","volume":"67","author":"AR Bedford-Russell","year":"1992","unstructured":"Bedford-Russell AR, Schwartz RH, Dawling S (1992) Accidental ingestion of \u201cecstasy\u201d (3,4-methylenedioxymethamphetamine). Arch Dis Child 67:1114\u20131115","journal-title":"Arch Dis Child"},{"key":"BF02246288_CR11","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/0140-6736(91)92332-V","volume":"338","author":"F Benazzi","year":"1991","unstructured":"Benazzi F, Mazzoli M (1991) Psychiatric illness associated with \u201cecstasy\u201d. Lancet 338:1520","journal-title":"Lancet"},{"key":"BF02246288_CR12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/0006-2952(84)90344-7","volume":"33","author":"S Boyce","year":"1984","unstructured":"Boyce S, Kelly E, Reavill C, Jenner P, Marsden CD (1984) Repeated administration of N-methyl-4-phenyl 1,2,5,6 tetrahydropyridine to rats is not toxic to striatal dopamine neurons. Biochem Pharmacol 33:1747\u20131752","journal-title":"Biochem Pharmacol"},{"key":"BF02246288_CR13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.1987.03400060056021","volume":"258","author":"C Brown","year":"1987","unstructured":"Brown C, Osterloh J (1987) Multiple severe complications from recreational ingestion of MDMA (\u201cEcstasy\u201d). J Am Med Assoc 258:780\u2013781","journal-title":"J Am Med Assoc"},{"key":"BF02246288_CR14","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","volume":"80","author":"RS Burns","year":"1983","unstructured":"Burns RS, Chieuh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983). A primate model of Parkinsonism: selective destruction of dopaminergic neurones in the pars compacta of the substantia nigra by 1-methyl-4-phenyl 1,2,3,6-tetra hydropyridine. Proc Nat Acad Sci USA 80:4546\u20134550","journal-title":"Proc Nat Acad Sci USA"},{"key":"BF02246288_CR15","first-page":"113","volume":"7","author":"CW Callaway","year":"1992","unstructured":"Callaway CW, Rempel N, Peng RY, Geyer MA (1992) Serotonin 5-HT1like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 7:113\u2013127","journal-title":"Neuropsychopharmacology"},{"key":"BF02246288_CR16","first-page":"61","volume":"85","author":"NTA Campkin","year":"1992","unstructured":"Campkin NTA, Davies UM (1992) Another death from ecstasy. J Roy Soc Med 85:61","journal-title":"J Roy Soc Med"},{"key":"BF02246288_CR17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/014107689108400622","volume":"84","author":"IS Chadwick","year":"1991","unstructured":"Chadwick IS, Linsley A, Freemont AJ, Doran B, Curry PD (1991) Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J Royal Soc Med 84:371","journal-title":"J Royal Soc Med"},{"key":"BF02246288_CR18","first-page":"214","volume":"87","author":"MRA Chance","year":"1946","unstructured":"Chance MRA (1946) Aggregation as a factor influencing the toxicity of sympathomimetic amines in mice. J Pharmacol Exp Ther 87:214\u2013219","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR19","first-page":"289","volume":"89","author":"MRA Chance","year":"1947","unstructured":"Chance MRA (1947) Factors influencing the toxicity of sympathomimetic amines to solitary mice. J Pharmacol Exp Ther 89:289\u2013296","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(84)90221-8","volume":"100","author":"CC Chieuh","year":"1984","unstructured":"Chieuh CC, Markey SP, Burns RS, Johannessen JN, Pert A, Kopin IJ (1984) Neurochemical and behavioural effects of systemic and intranigral administration ofN-methyl-4-phenyl 1,2,3,6-tetrahydropyridine in the rat. Eur J Pharmacol 100:189\u2013194","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1476-5381.1994.tb14034.x","volume":"111","author":"MI Colado","year":"1994","unstructured":"Colado MI, Green AR (1994) A study of the mechanism of MDMA (\u201cEcstasy\u201d)-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Br J Pharmacol 111:131\u2013136","journal-title":"Br J Pharmacol"},{"key":"BF02246288_CR22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1476-5381.1993.tb12846.x","volume":"108","author":"MI Colado","year":"1993","unstructured":"Colado MI, Murray, TK, Green AR (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA),p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108:583\u2013589","journal-title":"Br J Pharmacol"},{"key":"BF02246288_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0006-8993(87)90116-8","volume":"403","author":"DL Commins","year":"1987","unstructured":"Commins DL, Axt KJ, Vosmer G, Seiden LS (1987a) 5,6-Dihydroxytryptamine, a serotonergic neurotoxin is formed endogenously in rat brain. Brain Res 403:7\u201314","journal-title":"Brain Res"},{"key":"BF02246288_CR24","first-page":"338","volume":"241","author":"DL Commins","year":"1987","unstructured":"Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987b) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338\u2013345","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR25","first-page":"616","volume":"180","author":"AL Craig","year":"1972","unstructured":"Craig AL, Kupferberg HJ (1972) Hyperthermia andd-amphetamine toxicity in aggregated mice of different strains. J Pharmacol Exp Ther 180:616\u2013624","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1192\/bjp.159.5.713","volume":"159","author":"FJ Creighton","year":"1991","unstructured":"Creighton FJ, Black DL, Hyde CE (1991) \u201cEcstasy\u201d psychosis and flashbacks. Br J Psychiat 159:713\u2013715","journal-title":"Br J Psychiat"},{"key":"BF02246288_CR27","first-page":"60","volume":"39","author":"M Cursham","year":"1994","unstructured":"Cursham M, Dickson E, Kelly B, Kelly PAT, Neilson PP, Piper R. Reidy MJ, Ritchie IM, Sangra M, Stevens MC (1994) Focal hyperaemia in rat cortex following acute exposure to methylenedioxymethamphetamine (\u201cEcstasy\u201d). Scot Med J 39:60","journal-title":"Scot Med J"},{"key":"BF02246288_CR28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF02249342","volume":"114","author":"RI Dafters","year":"1994","unstructured":"Dafters RI (1994) Effects of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or \u201cecstasy\u201d) in rats. Psychopharmacology 114:505\u2013508","journal-title":"Psychopharmacology"},{"key":"BF02246288_CR29","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.1987.03390120077027","volume":"257","author":"GP Dowling","year":"1987","unstructured":"Dowling GP, McDonough ET, Bost RO (1987) Eve and Ecstasy, a report of five deaths associated with the use of MDEA and MDMA. JAMA 257:1615\u20131617","journal-title":"JAMA"},{"key":"BF02246288_CR30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/02791072.1986.10472366","volume":"18","author":"J Downing","year":"1986","unstructured":"Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoact Drugs 18:335\u2013340","journal-title":"J Psychoact Drugs"},{"key":"BF02246288_CR31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/0306-4522(79)90048-4","volume":"4","author":"A Dray","year":"1979","unstructured":"Dray A (1979) The striatum and substantia nigra:a commentary on their relationship. Neuroscience 4:1407\u20131439","journal-title":"Neuroscience"},{"key":"BF02246288_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bmj.305.6844.29","volume":"305","author":"IH Fahal","year":"1992","unstructured":"Fahal IH, Sallomi DF, Yaqoob M, Bell GM (1992) Acute renal failure after ecstasy. BMJ 305:29","journal-title":"BMJ"},{"key":"BF02246288_CR33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/0304-3940(89)90637-X","volume":"105","author":"KT Finnegan","year":"1990","unstructured":"Finnegan KT, Skratt JJ, Irwin I, Langston JW (1990) The N-methyl-d-aspartate (NMDA) receptor antagonist dextromethorphan prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurosci Lett 105:300\u2013306","journal-title":"Neurosci Lett"},{"key":"BF02246288_CR34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jama.1993.03500070049023","volume":"269","author":"R Friedman","year":"1993","unstructured":"Friedman R (1993) Ecstasy, the serotonin syndrome and neuroleptic malignant syndrome \u2014 a possible link? JAMA 269:869\u2013870","journal-title":"JAMA"},{"key":"BF02246288_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-2999(75)90145-4","volume":"33","author":"RW Fuller","year":"1975","unstructured":"Fuller RW, Perry KW, Molloy BB (1975) Reversible and irreversible phase of serotonin depletion by 4-chloroamphetamine. Eur J Pharmacol 33:119\u2013124","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-2999(89)90567-0","volume":"168","author":"RA Gazzara","year":"1989","unstructured":"Gazzara RA, Takeda H, Cho AK, Howard SG (1989) Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin. Eur J Pharmacol 168:209\u2013217","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1749-6632.1990.tb16913.x","volume":"600","author":"JW Gibb","year":"1990","unstructured":"Gibb JW, Johnson M, Stone D, Hanson GR (1990) MDMA: historical perspectives. Ann NY Acad Sci 600:601\u2013611","journal-title":"Ann NY Acad Sci"},{"key":"BF02246288_CR38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-73-1-81","volume":"73","author":"MD Ginsberg","year":"1970","unstructured":"Ginsberg MD, Herzman M, Schmidt-Nowara W (1970) Amphetamine intoxication with coagulopathy, hyperthermia and reversible renal failure. Ann Int Med 73:81\u201385","journal-title":"Ann Int Med"},{"key":"BF02246288_CR39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp.56.9.1036","volume":"56","author":"JA Gledhill","year":"1993","unstructured":"Gledhill JA, Moore DF, Bell D, Henry JA (1993) Subarachnoid haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiatry 56:1036\u20131037","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02246288_CR40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1476-5381.1985.tb16157.x","volume":"84","author":"GM Goodwin","year":"1985","unstructured":"Goodwin GM, Green AR (1985) A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol 84:743\u2013753","journal-title":"Br J Pharmacol"},{"key":"BF02246288_CR41","doi-asserted-by":"crossref","first-page":"5-6","DOI":"10.1007\/BF00690927","volume":"91","author":"GM Goodwin","year":"1987","unstructured":"Goodwin GM, De Souza, RJ, Green AR, Heal DJ (1987) The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Psychopharmacology 91:5-6\u20135-11","journal-title":"Psychopharmacology"},{"key":"BF02246288_CR42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.305.6848.309-a","volume":"305","author":"DA Gorard","year":"1992","unstructured":"Gorard DA, Davies SE, Clark ML (1992) Misuse of ecstasy. BMJ 305:309","journal-title":"BMJ"},{"key":"BF02246288_CR43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0091-3057(91)90288-D","volume":"38","author":"CJ Gordon","year":"1991","unstructured":"Gordon CJ, Wilkinson WP, O'Callaghan JP, Miller DB (1991) Effect of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 38:339\u2013344","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02246288_CR44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.1971.tb12034.x","volume":"18","author":"DG Grahame-Smith","year":"1971","unstructured":"Grahame-Smith DG (1971a) Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor andl-tryptophan. J Neurochem 18:1053\u20131066","journal-title":"J Neurochem"},{"key":"BF02246288_CR45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1476-5381.1971.tb07222.x","volume":"43","author":"DG Grahame-Smith","year":"1971","unstructured":"Grahame-Smith DG (1971b) Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced byl-tryptophan or 5-methoxy-N,N,dimethyl tryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol 43:856\u2013864","journal-title":"Br J Pharmacol"},{"key":"BF02246288_CR46","first-page":"161","volume-title":"Brain 5-HT1A Receptors","author":"AR Green","year":"1987","unstructured":"Green AR, Goodwin GM (1987) The pharmacology of the hypothermic response of rodents to 8-OH-DPAT administration and the effects of psychotropic drug administration on this response. In: Dourish CT, Ahlenius S, Hutson PH (eds) Brain 5-HT1A Receptors. Ellis Horwood, Chichester, pp 161\u2013176"},{"key":"BF02246288_CR47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/260487a0","volume":"260","author":"AR Green","year":"1976","unstructured":"Green AR, Grahame-Smith DG (1976) Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature 260:487\u2013491","journal-title":"Nature"},{"key":"BF02246288_CR48","first-page":"326","volume-title":"Neuropharmacology of serotonin","author":"AR Green","year":"1985","unstructured":"Green AR, Heal DJ (1985) The effects of drugs on serotonin-mediated behavioural models In: Green AR (ed) Neuropharmacology of serotonin. Oxford University Press, Oxford, pp 326\u2013365"},{"key":"BF02246288_CR49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1476-5381.1976.tb07664.x","volume":"57","author":"AR Green","year":"1976","unstructured":"Green AR, Kelly PH (1976) Evidence concerning the involvement of 5-hydroxytryptamine in locomotor activity produced by amphetamine or tranylcypromine plusl-dopa. Br J Pharmacol 57:141\u2013147","journal-title":"Br J Pharmacol"},{"key":"BF02246288_CR50","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1476-5381.1981.tb16806.x","volume":"73","author":"AR Green","year":"1981","unstructured":"Green AR, Hall JE, Rees AR (1981) A behavioural and biochemical study in rats of 5-hydroxytryptamine agonists and antagonists, with observations on structure-activity requirements for the agonists. Br J Pharmacol 73:703\u2013719","journal-title":"Br J Pharmacol"},{"key":"BF02246288_CR51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0028-3908(92)90062-T","volume":"31","author":"AR Green","year":"1992","unstructured":"Green AR, De Souza RJ, Williams JL, Murray TK, Cross AJ (1992) The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethiazole. Neuropharmacology 31:315\u2013321","journal-title":"Neuropharmacology"},{"key":"BF02246288_CR52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","volume":"18","author":"G Greer","year":"1986","unstructured":"Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoact Drugs 18:319\u2013327","journal-title":"J Psychoact Drugs"},{"key":"BF02246288_CR53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.psychotherapy.1986.40.3.393","volume":"40","author":"L Grinspoon","year":"1986","unstructured":"Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40:393\u2013404","journal-title":"Am J Psychother"},{"key":"BF02246288_CR54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archpsyc.1990.01810150088014","volume":"47","author":"C Grob","year":"1990","unstructured":"Grob C, Bravo G, Walsh R (1990) Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Arch Gen Psychiatry 47:288\u2013289","journal-title":"Arch Gen Psychiatry"},{"key":"BF02246288_CR55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1113\/jphysiol.1940.sp003822","volume":"97","author":"JA Gunn","year":"1940","unstructured":"Gunn JA, Gurd MR (1940) The action of some amines related to adrenaline. Cyclohexylalkylamines. J Physiol 97:453\u2013470","journal-title":"J Physiol"},{"key":"BF02246288_CR56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(85)90668-5","volume":"118","author":"E Habert","year":"1985","unstructured":"Habert E, Graham D, Tahaoui L, Claustre Y, Langer SZ (1985) Characterisation of [3H]-paroxetine binding to rat cortical membranes. Eur J Pharmacol 118:107\u2013114","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0041-008X(73)80016-X","volume":"25","author":"HF Hardman","year":"1973","unstructured":"Hardman HF, Haavik CO, Seevers MH (1973) Relationship of the structure of mescaline and seven analogs to toxicity and behaviour in five species of laboratory animals. Toxicol Appl Pharmacol 25:299\u2013309","journal-title":"Toxicol Appl Pharmacol"},{"key":"BF02246288_CR58","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/003693309203700508","volume":"37","author":"DP Harries","year":"1992","unstructured":"Harries DP, De Silva R (1992) Ecstasy and intracerebral haemorrhage. Scot Med J 37:150\u2013152","journal-title":"Scot Med J"},{"key":"BF02246288_CR59","first-page":"217","volume":"1","author":"JA Harvey","year":"1975","unstructured":"Harvey JA, McMaster SE (1975) Fenfluramine:evidence for a neurotoxic action in midbrain and a long term depletion of serotonin. Pharmacol Commun 1:217\u2013228","journal-title":"Pharmacol Commun"},{"key":"BF02246288_CR60","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00426832","volume":"49","author":"DJ Heal","year":"1976","unstructured":"Heal DJ, Green AR, Boullin DJ, Grahame-Smith DG (1976) Single and repeated administration of neuroleptic drugs to rats:effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine andl-tryptophan orl-dopa. Psychopharmacology 49:287\u2013300","journal-title":"Psychopharmacology"},{"key":"BF02246288_CR61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0014-2999(90)90555-K","volume":"177","author":"CR Hekmatpanah","year":"1990","unstructured":"Hekmatpanah CR, Peroutka SK (1990) 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur J Pharmacol 177:95\u201398","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1749-6632.1992.tb24558.x","volume":"648","author":"MG Henderson","year":"1992","unstructured":"Henderson MG, Hemrick-Luecke S, Fuller RW (1992) MK801 protects against amphetamine-induced striatal dopamine depletion in iprindole-treated rats, but not against brain serotonin depletion afterp-chloroamphetamine administration. Ann NY Acad Sci 648:286\u2013288","journal-title":"Ann NY Acad Sci"},{"key":"BF02246288_CR63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/bmj.305.6844.5","volume":"305","author":"JA Henry","year":"1992","unstructured":"Henry JA (1992) Ecstasy and the dance of death. BMJ 305:5\u20136.","journal-title":"BMJ"},{"key":"BF02246288_CR64","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0140-6736(92)91469-O","volume":"340","author":"JA Henry","year":"1992","unstructured":"Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d). Lancet 340:384\u2013387","journal-title":"Lancet"},{"key":"BF02246288_CR65","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/0028-3908(94)90134-1","volume":"33","author":"KE Hewitt","year":"1994","unstructured":"Hewitt KE, Green AR (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (\u201cEcstasy\u201d). Neuropharmacology 33:1589\u20131595","journal-title":"Neuropharmacology"},{"key":"BF02246288_CR66","first-page":"521","volume":"254","author":"M Hiramatsu","year":"1990","unstructured":"Hiramatsu M, Kumagai Y, Unger SE, Cho AK (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254:521\u2013527","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR67","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01276574","volume":"55","author":"S Hj\u00f6rth","year":"1982","unstructured":"Hj\u00f6rth S, Carlsson A, Lindberg P, Sanchez D, Wikstrom H, Arvidsson LE, Hacksell U, Nilsson JLG (1982) 8-Hydroxy-2-(di-n-prolylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity. J Neural Transm 55:169\u2013188","journal-title":"J Neural Transm"},{"key":"BF02246288_CR68","first-page":"257","volume":"214","author":"A Hotchkiss","year":"1980","unstructured":"Hotchkiss A, Gibb JW (1980) Long term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase in rat brain. J Pharmacol Exp Ther 214:257\u2013262.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-6147(93)90016-D","volume":"14","author":"PPA Humphrey","year":"1993","unstructured":"Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233\u2013236","journal-title":"Trends Pharmacol Sci"},{"key":"BF02246288_CR70","first-page":"713","volume":"249","author":"TR Insel","year":"1989","unstructured":"Insel TR, Battaglia G, Johanssen J, Marra S, De Souza EB (1989) 3,4-Methylenedioxymethamphetamine (\u201cEcstasy\u201d) selectively destroys brain serotonin nerve terminals in rhesus monkeys. J Pharmacol Exp Ther 249:713\u2013720","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR71","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-2999(86)90615-1","volume":"132","author":"MP Johnson","year":"1986","unstructured":"Johnson MP, Hoffman AJ, Nichols, DE (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269\u2013276","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0014-2999(89)90728-0","volume":"165","author":"MP Johnson","year":"1989","unstructured":"Johnson MP, Hanson GR, Gibb JW (1989) Effect of MK801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog. Eur J Pharmacol 165:315\u2013318","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR73","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0091-3057(91)90106-C","volume":"40","author":"MP Johnson","year":"1991","unstructured":"Johnson MP, Huang X, Nichols DE (1991) Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a non-neurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol Biochem Behav 40:915\u2013922","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02246288_CR74","first-page":"447","volume":"261","author":"MP Johnson","year":"1992","unstructured":"Johnson MP, Elayan I, Hanson GR, Foltz RL, Gibb JW, Lim HK (1992) Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and doopaminergic systems. J Pharmacol Exp Ther 261:447\u2013453","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR75","unstructured":"Kaufmann CA, Wyatt RJ, Meltzer Hy (ed) Neuroleptic malignant syndrome. In: Psychopharmacology; the third generation of progress. In: Raven Press, New York pp 1421\u20131430"},{"key":"BF02246288_CR76","first-page":"421","volume":"160","author":"RW Kay","year":"1992","unstructured":"Kay RW (1992) Prevalence and incidence of schizophrenia in Afro-Caribbeans. Br J Psychiatry 160:421","journal-title":"Br J Psychiatry"},{"key":"BF02246288_CR77","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/0006-3223(89)90270-9","volume":"25","author":"Y Kazahara","year":"1989","unstructured":"Kazahara Y, Akimoto K, Otsuki S (1989) Subchronic methamphetamine treatment enhances methamphetamine or cocaine induced dopamine efflux in vivo. Biol Psychiatry 25:903\u2013912","journal-title":"Biol Psychiatry"},{"key":"BF02246288_CR78","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/0003-4819-86-4-381","volume":"86","author":"WC Kendrick","year":"1977","unstructured":"Kendrick WC, Hull AR, Krockel JP (1977) Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Int Med 86:381\u2013387","journal-title":"Ann Int Med"},{"key":"BF02246288_CR79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0006-8993(89)90700-2","volume":"448","author":"MS Kleven","year":"1989","unstructured":"Kleven MS, Woolverton WL, Seiden LS (1989) Evidence that both intragastric and subcutaneously administered MDMA produce 5-HT neurotoxicity in rhesus monkeys. Brain Res 448:121\u2013125","journal-title":"Brain Res"},{"key":"BF02246288_CR80","first-page":"42","volume":"185","author":"LY Koda","year":"1973","unstructured":"Koda LY, Gibb JW (1973) Adrenal and striatal tyrosine hydroxylase activity after methamphetamine. J Pharmacol Exp Ther 185:42\u201348","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR81","first-page":"359","volume":"45","author":"Y Kumagai","year":"1994","unstructured":"Kumagai Y, Lin LY, Hiratsuka A, Narimatsu S, Suzuki T, Yamada H, Oguri K, Yoshimura H, Cho AK (1994) Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymeth-amphetamine enantiomers by rats. Mol Pharmacol 45:359\u2013365","journal-title":"Mol Pharmacol"},{"key":"BF02246288_CR82","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard PA, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidone-analog synthesis. Science (Wash) 219:979\u2013980","journal-title":"Science"},{"key":"BF02246288_CR83","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","volume":"292","author":"JW Langston","year":"1984","unstructured":"Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292:390\u2013394","journal-title":"Brain Res"},{"key":"BF02246288_CR84","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0014-2999(90)93339-R","volume":"183","author":"R Laverty","year":"1990","unstructured":"Laverty R, Logan BJ (1990) Protection by MK 801 and other drugs of methylenedioxymethamphetamine (MDMA) neurotoxicity in rats and mice. Eur J Pharmacol 183:451\u2013452","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR85","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1021\/tx00024a004","volume":"4","author":"HK Lim","year":"1991","unstructured":"Lim HK, Folz RL (1991) Ion trap mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. Chem Res Toxicol 4:626\u2013632","journal-title":"Chem Res Toxicol"},{"key":"BF02246288_CR86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-2999(88)90717-0","volume":"152","author":"BJ Logan","year":"1988","unstructured":"Logan BJ, Laverty R, Sanderson WD, Yee YB (1988) Differences between rats and mice in MDMA (methylenedioxymethamphetamine) neurotoxicity. Eur J Pharmacol 152:227\u2013234","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR87","first-page":"525","volume":"88","author":"RA Lyon","year":"1986","unstructured":"Lyon RA, Glennon RA, Titeler M (1986) 3,4-methylenemethoxymethamphetamine (MDMA):stereoselective interactions at 5-HT1 and 5-HT2 receptors. Psychopharmacology 88:525\u2013526","journal-title":"Psychopharmacology"},{"key":"BF02246288_CR88","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00004714-199110000-00005","volume":"11","author":"UD McCann","year":"1991","unstructured":"McCann UD, Ricaurte GA (1991) Lasting neuropsychiatric sequelae of (+)-methylenedioxymethamphetamine (\u201cEcstasy\u201d) in recreational users. J Clin Psychopharmacol 11:302\u2013305","journal-title":"J Clin Psychopharmacol"},{"key":"BF02246288_CR89","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00004714-199306000-00011","volume":"13","author":"UD McCann","year":"1993","unstructured":"McCann UD, Ricaurte GA (1993) Reinforcing subjective effects of (+)-3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d) may be separable for its neurotoxic actions:clinical evidence. J Clin Psychopharmacol 13:214\u2013217","journal-title":"J Clin Psychopharmacol"},{"key":"BF02246288_CR90","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bmj.302.6778.697","volume":"302","author":"P McGuire","year":"1991","unstructured":"McGuire P, Fahy T (1991) Chronic paranoid psychosis after misuse of MDMA (\u201cEcstasy\u201d). BMJ 302:697","journal-title":"BMJ"},{"key":"BF02246288_CR91","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1192\/bjp.163.5.698a","volume":"163","author":"P McGuire","year":"1993","unstructured":"McGuire P, Jones P, Murray R (1993) Psychiatric symptoms in cannabis users. Br J Psychiatry 163:698","journal-title":"Br J Psychiatry"},{"key":"BF02246288_CR92","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1192\/bjp.165.3.391","volume":"165","author":"PK McGuire","year":"1994","unstructured":"McGuire PK, Cope H, Fahy TA (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine (\u201cEcstasy\u201d). Br J Psychiatry 165:391\u2013395","journal-title":"Br J Psychiatry"},{"key":"BF02246288_CR93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1471-4159.1990.tb13277.x","volume":"54","author":"DJ McKenna","year":"1990","unstructured":"McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d). J Neurochem 54:14\u201322","journal-title":"J Neurochem"},{"key":"BF02246288_CR94","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1749-6632.1993.tb18315.x","volume":"679","author":"DB Miller","year":"1993","unstructured":"Miller DB, O'Callaghan JP (1993) The interactions of MK801 with the amphetamine analoguesd-methamphetamine (d-METH), 3,4-methylenedioxymethamphetamine (d-MDMA) ord-fenfluramine (d-FEN); neural damage and neural protection. Ann NY Acad Sci 679:321\u2013324","journal-title":"Ann NY Acad Sci"},{"key":"BF02246288_CR95","first-page":"752","volume":"270","author":"DB Miller","year":"1994","unstructured":"Miller DB, O'Callaghan JP (1994) Environment and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL\/6J mouse. J Pharmacol Exp Ther 270:752\u2013760","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR96","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-2999(87)90441-9","volume":"138","author":"DJ Mokler","year":"1987","unstructured":"Mokler DJ, Robinson SE, Rosecrans JA (1987) (+)-3,4-Methylenedioxymethamphetamine produces long-term reductions in brain 5-hydroxytryptamine in rats. Eur J Pharmacol 138:265\u2013268","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR97","first-page":"1234","volume":"12","author":"ME Molliver","year":"1986","unstructured":"Molliver ME, O'Hearn E, Battaglia G, De Souza EB (1986) Direct intracerebral administrations of MDA and MDMA does not produce serotonin neurotoxicity. Soc Neurosci Abst 12:1234","journal-title":"Soc Neurosci Abst"},{"key":"BF02246288_CR98","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1749-6632.1990.tb16916.x","volume":"600","author":"ME Molliver","year":"1990","unstructured":"Molliver ME, Berger UV, Mamounas LA, Molliver DL, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds:anatomic studies. Ann NY Acad Sci 600:640\u2013661","journal-title":"Ann NY Acad Sci"},{"key":"BF02246288_CR99","first-page":"873","volume":"245","author":"JF Nash","year":"1988","unstructured":"Nash JF, Meltzer HY, Gudelsky GA (1988) Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245:873\u2013879","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0006-2952(91)90013-U","volume":"41","author":"JF Nash","year":"1991","unstructured":"Nash JF, Arora RC, Schreiber MA, Meltzer HY (1991) Effect of 3,4-methylenedioxymethamphetamine on [3H]-paroxetine binding in the frontal cortex and blood platelets of rats. Biochem Pharmacol 41:79\u201384","journal-title":"Biochem Pharmacol"},{"key":"BF02246288_CR101","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00965628","volume":"1","author":"NM Neckers","year":"1976","unstructured":"Neckers NM, Bertilsson L, Costa E (1976) The action of fenfluramine andp-chloroamphetamine on serotonergic mechanisms: a comparable study in rat brain nuclei. Neurochem Res 1:29\u201335","journal-title":"Neurochem Res"},{"key":"BF02246288_CR102","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1523\/JNEUROSCI.08-08-02788.1988","volume":"8","author":"E O'Hearn","year":"1988","unstructured":"O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylene-dioxymethamphetamine (MDMA) cause ablation of serotonergic axon terminals in forebrain:immunocytochemical evidence. J Neurosci 8:2788\u20132803","journal-title":"J Neurosci"},{"key":"BF02246288_CR103","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0361-9230(92)90237-R","volume":"28","author":"JM Paris","year":"1992","unstructured":"Paris JM, Cunningham KA (1992) Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine. Brain Res Bull 28:115\u2013119","journal-title":"Brain Res Bull"},{"key":"BF02246288_CR104","first-page":"1542","volume":"317","author":"SJ Peroutka","year":"1987","unstructured":"Peroutka SJ (1987) Incidence of recreational use of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) on an undergraduate campus. N Engl J Med 317:1542\u20131543","journal-title":"N Engl J Med"},{"key":"BF02246288_CR105","first-page":"273","volume":"1","author":"SJ Peroutka","year":"1988","unstructured":"Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273\u2013278","journal-title":"Neuropsychopharmacology"},{"key":"BF02246288_CR106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archpsyc.1989.01810010022003","volume":"46","author":"LP Price","year":"1989","unstructured":"Price LP, Ricaurte GA, Krystal JH, Heninger GR (1989) Neuroendocrine and mood response tol-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Arch Gen Psychiat 46:20\u201322","journal-title":"Arch Gen Psychiat"},{"key":"BF02246288_CR107","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jama.268.12.1505","volume":"268","author":"J Randall","year":"1992","unstructured":"Randall J (1992a) Ecstasy-fueled \u201crave\u201d parties become dances of death for English youths. JAMA 268:1505\u20131506","journal-title":"JAMA"},{"key":"BF02246288_CR108","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jama.1992.03490120010003","volume":"268","author":"T Randall","year":"1992","unstructured":"Randall T (1992b) Rave scene, ecstasy use, leap Atlantic. JAMA 268:1506","journal-title":"JAMA"},{"key":"BF02246288_CR109","first-page":"77","volume":"26","author":"M Rattray","year":"1991","unstructured":"Rattray M (1991) Ecstasy:towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem 26:77\u201387","journal-title":"Essays Biochem"},{"key":"BF02246288_CR110","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.4023719","volume":"229","author":"G Ricaurte","year":"1985","unstructured":"Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985) Hallucinogenic amphetamine selectively destroys brain serotonin terminals. Science 229:986\u2013988","journal-title":"Science"},{"key":"BF02246288_CR111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0006-8993(88)90451-9","volume":"474","author":"GA Ricaurte","year":"1988","unstructured":"Ricaurte GA, De Lanney LE, Wiener SG, Irwin I, Langston JW (1988a) 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res 474:359\u2013363","journal-title":"Brain Res"},{"key":"BF02246288_CR112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1988.03410010059035","volume":"260","author":"GA Ricaurte","year":"1988","unstructured":"Ricaurte GA, Forno LS, Wilson MA, De Lanney LE, Irwin I, Molliver ME, Langston JW (1988b) MDMA selectively damages central serotonergic neurons in the primate. JAMA 260:51\u201355","journal-title":"JAMA"},{"key":"BF02246288_CR113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-8993(88)91309-1","volume":"446","author":"GA Ricaurte","year":"1988","unstructured":"Ricaurte GA, Delanney LE, Irwin I, Langston JW (1988c) Toxic effects of MDMA on central serotonergic neurons in the primate:importance of route and frequency of drug administration. Brain Res 446:165\u2013168","journal-title":"Brain Res"},{"key":"BF02246288_CR114","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1749-6632.1990.tb16919.x","volume":"600","author":"GA Ricaurte","year":"1990","unstructured":"Ricaurte GA, Finnegan KT, Irwin I, Langston JW (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA:preliminary observations. Ann NY Acad Sci 600:699\u2013710","journal-title":"Ann NY Acad Sci"},{"key":"BF02246288_CR115","first-page":"616","volume":"261","author":"GA Ricaurte","year":"1992","unstructured":"Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of (\u00b1)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in non human primates:neurochemical observations. J Pharmacol Exp Ther 261:616\u2013621","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR116","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1192\/bjp.163.6.798","volume":"163","author":"M Rolfe","year":"1993","unstructured":"Rolfe M, Tange CM, Sabally S, Todd JE, Sam EB, Hatib Njie AB (1993) Psychosis and cannabis abuse in the Gambia. A case-control study. Br J Psychiatry 163:798\u2013801","journal-title":"Br J Psychiatry"},{"key":"BF02246288_CR117","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0006-8993(92)90326-5","volume":"582","author":"KE Sabol","year":"1992","unstructured":"Sabol KE, Richards JB, Seiden LS (1992) The NMDA receptor antagonist MK801 does not protect against serotonin depletions caused by high does ofDl-fenfluramine. Brain Res 582:129\u2013133","journal-title":"Brain Res"},{"key":"BF02246288_CR118","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0014-2999(72)90204-X","volume":"20","author":"E Sanders-Bush","year":"1972","unstructured":"Sanders-Bush E, Bushing JA, Sulser F (1972) Long term effect ofp-chloroamphetamine on tryptophan hydroxylase activity and on the levels of 5-hydroxytryptamine and 5-hydroxyindole acetic acid in brain. Eur J Pharmacol 20:385\u2013388","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR119","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/bmj.305.6848.310","volume":"305","author":"J Sawyer","year":"1992","unstructured":"Sawyer J, Stephens WP (1992) Misuse of ecstasy. BMJ 305:310","journal-title":"BMJ"},{"key":"BF02246288_CR120","first-page":"1484","volume":"264","author":"CR Scanzello","year":"1993","unstructured":"Scanzello CR (1993) Hatzidimitriou G, Martello AL, Katz JL, Ricuarte GA (1993) Serotonergic recovery after (+)-3,4-(methylene-dioxy)methamphetamine injury:observations in rats. J Pharmacol Exp Ther 264:1484\u20131491","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR121","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/0140-6736(91)92633-D","volume":"338","author":"F Schifano","year":"1991","unstructured":"Schifano F (1991) Chronic atypical psychosis associated with MDMA (\u201cEcstasy\u201d) abuse. Lancet 338:1335","journal-title":"Lancet"},{"key":"BF02246288_CR122","first-page":"1","volume":"240","author":"CJ Schmidt","year":"1987","unstructured":"Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1\u20137","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR123","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1749-6632.1990.tb16917.x","volume":"600","author":"CJ Schmidt","year":"1990","unstructured":"Schmidt CJ, Kehne JH (1990) Neurotoxicity of MDMA:neurochemical effects. Ann NY Acad Sci 1990; 600:665\u2013681","journal-title":"Ann NY Acad Sci 1990"},{"key":"BF02246288_CR124","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1016\/0006-2952(87)90566-1","volume":"36","author":"CJ Schmidt","year":"1987","unstructured":"Schmidt CJ, Taylor VL (1987) Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36:4095\u20134102","journal-title":"Biochem Pharmacol"},{"key":"BF02246288_CR125","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0014-2999(86)90140-8","volume":"124","author":"CJ Schmidt","year":"1986","unstructured":"Schmidt CJ, Wu L, Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 124:175\u2013178","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR126","first-page":"747","volume":"36","author":"CJ Schmidt","year":"1987","unstructured":"Schmidt CJ, Levin JA, Lovenberg W (1987) In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 1987; 36:747\u2013755","journal-title":"Biochem Pharmacol 1987"},{"key":"BF02246288_CR127","first-page":"478","volume":"255","author":"CJ Schmidt","year":"1990","unstructured":"Schmidt CJ, Abbate GM, Black CK, Taylor VL (1990a) Selective 5-HT2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 255:478\u2013483","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-8993(90)90813-Q","volume":"529","author":"CJ Schmidt","year":"1990","unstructured":"Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990b) MDMA-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2receptors. Brain Res 529:85\u201390","journal-title":"Brain Res"},{"key":"BF02246288_CR129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(90)90245-2","volume":"181","author":"CJ Schmidt","year":"1990","unstructured":"Schmidt CJ, Black CK, Taylor VL (1990c) Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur J Pharmacol 181:59\u201370","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0014-2999(91)90788-R","volume":"203","author":"CJ Schmidt","year":"1991","unstructured":"Schmidt CJ, Black CK, Taylor VL (1991a) L-Dopa potentiation of serotonergic deficits due to a single administration of 3,4-methylenedioxy-methamphetamine,p-chloroamphetamine or methamphetamine to rats. Eur J Pharmacol 203:41\u201349","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR131","first-page":"230","volume":"256","author":"CJ Schmidt","year":"1991","unstructured":"Schmidt CJ, Taylor VL, Abbate GM, Nieduzak TR (1991b) 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal byl-Dopa. J Pharmacol Exp Ther 256:230\u2013235","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR132","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0140-6736(92)90834-P","volume":"339","author":"GR Screaton","year":"1992","unstructured":"Screaton GR, Singer M, Cairns HS, Thrasher A, Sarner M, Cohen SL (1992) Hyperpyrexia and rhabdomyolysis after MDMA (\u201cEcstasy\u201d) abuse. Lancet 339:677\u2013678","journal-title":"Lancet"},{"key":"BF02246288_CR133","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1749-6632.1990.tb16920.x","volume":"600","author":"LS Seiden","year":"1990","unstructured":"Seiden LS (1990) MDMA and related compounds:session summary. Ann NY Acad Sci 600:711\u2013715","journal-title":"Ann NY Acad Sci"},{"key":"BF02246288_CR134","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF02316872","volume":"105","author":"J Sharkey","year":"1991","unstructured":"Sharkey J, McBean DE, Kelly PAT (1991) Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxy-amphetamine (\u201cEcstasy\u201d). Psychopharmacology 105:113\u2013118","journal-title":"Psychopharmacology"},{"key":"BF02246288_CR135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.305.6848.309","volume":"305","author":"JD Shearman","year":"1992","unstructured":"Shearman JD, Satsangi J, Chapman RWG, Ryley NG, Weatherhead S (1992) Misuse of ecstasy. BMJ 305:309","journal-title":"BMJ"},{"key":"BF02246288_CR136","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/archinte.1981.00340120115023","volume":"141","author":"DL Simpson","year":"1981","unstructured":"Simpson DL, Rumack BH (1981) Methylenedioxyamphetamine, clinical description of overdose, death and review of pharmacology. Arch Int Med 141:1507\u20131509","journal-title":"Arch Int Med"},{"key":"BF02246288_CR137","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2044.1992.tb02391.x","volume":"47","author":"C Singarajah","year":"1992","unstructured":"Singarajah C, Lavies NG (1992) An overdose of ecstasy:a role for dantrolene. Anaesthesia 47:686\u2013687","journal-title":"Anaesthesia"},{"key":"BF02246288_CR138","first-page":"529","volume":"10","author":"W Slikker Jr","year":"1989","unstructured":"Slikker W Jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, Scalzo FM (1989) Behavioural and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10:529\u2013542","journal-title":"Neurotoxicology"},{"key":"BF02246288_CR139","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/15563658708992620","volume":"25","author":"MJ Smilkstein","year":"1987","unstructured":"Smilkstein MJ, Smolinske SC, Rumack BH (1987) A case of MAO inhibitor\/MDMA interaction:agony after ecstasy. J Toxicol Clin Toxicol 25:149\u2013159","journal-title":"J Toxicol Clin Toxicol"},{"key":"BF02246288_CR140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-0773.1994.tb01071.x","volume":"14","author":"MF Snape","year":"1994","unstructured":"Snape MF, Colado MI, Green AR (1994) Chlormethiazole and dizocilpine block the behavioural but not the neurotoxic effects of 5,7-dihydroxytryptamine in mice. Pharmacol Toxicol 14:40\u201342","journal-title":"Pharmacol Toxicol"},{"key":"BF02246288_CR141","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1126\/science.2563176","volume":"243","author":"PK Sonsalla","year":"1989","unstructured":"Sonsalla PK, Nicklas WJ, Keikkila RE (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science, Wash 243:398\u2013400","journal-title":"Science, Wash"},{"key":"BF02246288_CR142","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0091-3057(89)90044-0","volume":"32","author":"LJ Spanos","year":"1989","unstructured":"Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(+)-MDMA] on locomotion and serotonin syndrome behaviour in the rat. Pharmacol Biochem Behav 32:835\u2013840","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02246288_CR143","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/0006-2952(87)90594-6","volume":"36","author":"TD Steele","year":"1987","unstructured":"Steele TD, Nichols DE, Yim GKW (1987) Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]-monoamines into synaptosomes for different regions of rat brain. Biochem Pharmacol 36:2297\u20132303","journal-title":"Biochem Pharmacol"},{"key":"BF02246288_CR144","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","volume":"148","author":"H Sternbach","year":"1991","unstructured":"Sternbach H (1991) The serotonin syndrome. Am J Psychiat 148:705\u2013713","journal-title":"Am J Psychiat"},{"key":"BF02246288_CR145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0014-2999(86)90555-8","volume":"128","author":"DM Stone","year":"1986","unstructured":"Stone DM, Stahl DC, Hanson GR, Gibb JW (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128:41\u201348","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR146","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/0028-3908(87)90117-1","volume":"26","author":"DM Stone","year":"1987","unstructured":"Stone DM, Merchant KM, Hanson GR, Gibb JW (1987) Immediate and long term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677\u20131683","journal-title":"Neuropharmacology"},{"key":"BF02246288_CR147","first-page":"79","volume":"247","author":"DM Stone","year":"1988","unstructured":"Stone DM, Johnson M, Hanson GR, Gibb JW (1988) Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 247:79\u201387","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02246288_CR148","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0922-4106(89)90048-5","volume":"172","author":"DM Stone","year":"1989","unstructured":"Stone DM, Johnson M, Hansson GR, Gibb JW (1989) Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulphydryl sites. Eur J Pharmacol 172:93\u201397","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR149","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1192\/bjp.164.4.474","volume":"164","author":"PA Sugarman","year":"1994","unstructured":"Sugarman PA, Craufurd D (1994) Schizophrenia in the Afro-Caribbean community. Br J Psychiat 164:474\u2013480","journal-title":"Br J Psychiat"},{"key":"BF02246288_CR150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/bmj.306.6870.146","volume":"306","author":"B Tehan","year":"1993","unstructured":"Tehan B (1993) Ecstasy and dantrolene. BMJ 306:146","journal-title":"BMJ"},{"key":"BF02246288_CR151","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-2999(84)90714-3","volume":"106","author":"MD Tricklebank","year":"1984","unstructured":"Tricklebank MD, Forler C, Fozard JR (1984) The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106:271\u2013282","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR152","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0014-2999(76)90266-1","volume":"36","author":"ME Trulson","year":"1976","unstructured":"Trulson ME, Jacobs BL (1976) Behavioural evidence for the rapid release of CNS serotonin by PCA and fenfluramine. Eur J Pharmacol 36:149\u2013154","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR153","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/0006-2952(94)90386-7","volume":"47","author":"GT Tucker","year":"1994","unstructured":"Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY (1994) The demethylenation of methylenedioxymethamphetamine (\u201cEcstasy\u201d) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151\u20131156","journal-title":"Biochem Pharmacol"},{"key":"BF02246288_CR154","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1001\/jama.259.11.1649","volume":"259","author":"K Verebey","year":"1988","unstructured":"Verebey K, Alrazi J, Jeffe JH (1988) The complications of ecstasy (MDMA). JAMA 259:1649\u20131650","journal-title":"JAMA"},{"key":"BF02246288_CR155","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0014-2999(87)90485-7","volume":"138","author":"SS Wang","year":"1987","unstructured":"Wang SS, Ricuarte GA, Peroutka SJ (1987) [3H]-3,4-Methylenedioxy-methamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper. Eur J Pharmacol 138:439\u2013443","journal-title":"Eur J Pharmacol"},{"key":"BF02246288_CR156","first-page":"119","volume":"146","author":"PM Whitaker-Azmitia","year":"1989","unstructured":"Whitaker-Azmitia PM, Aronson TA (1989) \u201cEcstasy\u201d (MDMA)-induced panic. Am J Psychiatry 146:119","journal-title":"Am J Psychiatry"},{"key":"BF02246288_CR157","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4522(89)90237-6","volume":"28","author":"MA Wilson","year":"1989","unstructured":"Wilson MA, Ricaurte GA, Molliver ME (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28:121\u2013137","journal-title":"Neuroscience"},{"key":"BF02246288_CR158","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/bmj.302.6785.1150-b","volume":"302","author":"AR Winstock","year":"1991","unstructured":"Winstock AR (1991) Chronic paranoid psychosis after misuse of 3,4-methylenedioxymethamphetamine. BMJ 302:1150\u20131151","journal-title":"BMJ"},{"key":"BF02246288_CR159","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.2042-7158.1973.tb10044.x","volume":"25","author":"HH Wolf","year":"1973","unstructured":"Wolf HH, Bunce ME (1973) Hyperthermia and the amphetamine aggregation phenomenon:absence of a causal relation. J Pharm Pharmacol 25:425\u2013427","journal-title":"J Pharm Pharmacol"},{"key":"BF02246288_CR160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0140-6736(92)92392-S","volume":"340","author":"JD Woods","year":"1992","unstructured":"Woods JD, Henry JA (1992) Hyperpyrexia induced by 3,4-methylenedioxyamphetamine (\u201cEve\u201d). Lancet 340:305","journal-title":"Lancet"},{"key":"BF02246288_CR161","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/0006-2952(91)90653-M","volume":"41","author":"MZ Wrona","year":"1991","unstructured":"Wrona MZ, Dryhurst G (1991) Interactions of 5-hydroxytryptamine with oxidative enzymes. Biochem Pharmacol 41:1145\u20131162","journal-title":"Biochem Pharmacol"},{"key":"BF02246288_CR162","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1001\/jama.1986.03380220011003","volume":"256","author":"T Ziporyn","year":"1986","unstructured":"Ziporyn T (1986) A growing industry and menace: Makeshrift laboratory's designer drugs. JAMA 256:3061\u20133063","journal-title":"JAMA"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02246288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02246288\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02246288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:30:17Z","timestamp":1558002617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02246288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,6]]},"references-count":162,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,6]]}},"alternative-id":["BF02246288"],"URL":"https:\/\/doi.org\/10.1007\/bf02246288","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,6]]}}}